Neurodevelopmental Outcomes clinical trials

Explore recruiting neurodevelopmental outcomes clinical trials.

Recruiting neurodevelopmental outcomes studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neurodevelopmental Outcomes trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study

Romania, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Does the Use of Higher Versus Lower Oxygen Concentration Improve Neurodevelopmental Outcomes at 24 Months (plus or minus 6 months) in Very Low Birthweight Infants: The HiLo-Trial

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

(20275) An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090

Sweden, Italy, Portugal, Bulgaria, Romania, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

ACUMEN: Phase I Dose Escalation and Cohort Expansion study to affirm the safety of pharmacological doses of a novel formulation of intravenous melatonin in babies with hypoxic-ischaemic encephalopathy (HIE) to augment therapeutic hypothermia (HT) treatment; to reduce the incidence and severity of disability in babies with moderate-severe HIE.

Ireland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Neurodevelopmental Outcomes trials by city

Neurodevelopmental Outcomes in Toronto Neurodevelopmental Outcomes in Vancouver Neurodevelopmental Outcomes in Montreal Neurodevelopmental Outcomes in Calgary Neurodevelopmental Outcomes in Edmonton Neurodevelopmental Outcomes in Ottawa Neurodevelopmental Outcomes in Winnipeg Neurodevelopmental Outcomes in Quebec City Neurodevelopmental Outcomes in Hamilton Neurodevelopmental Outcomes in Kitchener Neurodevelopmental Outcomes in London Neurodevelopmental Outcomes in Halifax Neurodevelopmental Outcomes in New York Neurodevelopmental Outcomes in Los Angeles Neurodevelopmental Outcomes in Chicago Neurodevelopmental Outcomes in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease